Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.74 |
| ▸ | RARB | P10826 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 7/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6555070 | 1.00 | ADORA2B (0.74) | ADORA2BADORA3ADORA2AADORA1RARB | |
| SCHEMBL5616731 | 1.00 | ADORA2B (0.74) | ADORA2BADORA3ADORA2AADORA1RARB | |
| SCHEMBL6555076 | 1.00 | ADORA2B (0.74) | ADORA2BADORA3ADORA2AADORA1RARB | |
| Hydrochloric Acid SCHEMBL6554025 | 0.99 | ADORA2B (0.73) | ADORA2BADORA3ADORA2AADORA1RARB | |
| SCHEMBL6554054 | 0.99 | ADORA2B (0.72) | ADORA2BADORA3ADORA2AADORA1RARB | |
| SCHEMBL6554049 | 0.99 | ADORA2B (0.72) | ADORA2BADORA3ADORA2AADORA1RARB | |
| Ethylene SCHEMBL6745654 | 0.98 | ADORA2B (0.74) | ADORA2BADORA3ADORA2AADORA1RARB | |
| Ethylene SCHEMBL6745653 | 0.98 | ADORA2B (0.74) | ADORA2BADORA3ADORA2AADORA1RARB | |
| Ethylene SCHEMBL7664290 | 0.98 | ADORA2B (0.74) | ADORA2BADORA3ADORA2AADORA1RARB | |
| Ethylene SCHEMBL7664296 | 0.98 | ADORA2B (0.74) | ADORA2BADORA3ADORA2AADORA1RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7002012-B2 | Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-YI)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-21 | — | — | US | claimed |
| US-20020035156-A1 | Combination therapy in the prevention of cardiovascular disorders | RONIKER BARBARA (US) | 2002-03-21 | — | — | US | claimed |
| EP-0775141-B1 | PHENYL XANTHINE DERIVATIVES | WELLCOME FOUND (GB) | 2001-09-26 | — | — | EP | claimed |
| US-20070072861-A1 | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders | RONIKER BARBARA | 2007-03-29 | — | — | US | disclosed |
| US-7002012-B2 | Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-YI)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-21 | — | — | US | disclosed |
| EP-0970081-B1 | SUBSTITUTED (1,3-BIS(CYCLOHEXYLMETHYL)-1,2,3,6-TETRAHYDRO-2,6-DIOXO-9H-PURIN-8-YL)PHENYL DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INFLAMMATORY CONDITIONS AND IMMUNE DISORDERS | GLAXO GROUP LTD (GB) | 2005-09-14 | — | — | EP | disclosed |
| US-6770267-B2 | Methods of treating periodontal disease | SMITHKLINE BEECHAM CORPORATION | 2004-08-03 | — | — | US | disclosed |
| US-20040034020-A1 | Methods of treating periodontal disease | DALUGE SUSAN MARY (US) | 2004-02-19 | — | — | US | disclosed |
| EP-1104422-B1 | PHENYL XANTHINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2004-02-18 | — | — | EP | disclosed |
| US-20030181471-A1 | Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-YI)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders | DALUGE SUSAN MARY (US) | 2003-09-25 | — | — | US | disclosed |
| US-6608069-B1 | Treating AIDS-related diarrhea or infectious diarrhea, tissue damage or dermatitis associated with leukocyte infiltration into tissue, asthma, inflammatory bowel condition, eczema, or psoriasis | SMITHKLINE BEECHAM CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-6355646-B1 | IMMUNOLOGY TREATMENT OF INFLAMMATORY CONDITIONS AND IMMUNE DISORDERS SEPTIC SHOCK | GLAXO WELLCOME INC. | 2002-03-12 | — | — | US | disclosed |
| EP-0775141-B1 | PHENYL XANTHINE DERIVATIVES | WELLCOME FOUND (GB) | 2001-09-26 | — | — | EP | disclosed |
| EP-1104422-A1 | PHENYL XANTHINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009507-A1 | PHENYL YANTHINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-02-24 | — | — | WO | disclosed |
| EP-0970081-A1 | SUBSTITUTED (1,3-BIS(CYCLOHEXYLMETHYL)-1,2,3,6-TETRAHYDRO-2,6-DIOXO-9H-PURIN-8-YL)PHENYL DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INFLAMMATORY CONDITIONS AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998035966-A1 | SUBSTITUTED (1,3-BIS(CYCLOHEXYLMETHYL)-1,2,3,6-TETRAHYDRO-2,6-DIOXO-9H-PURIN-8-YL)PHENYL DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INFLAMMATORY CONDITIONS AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 1998-08-20 | — | — | WO | disclosed |
| US-5776940-A | COMPOUNDS FOR TREATMENT OF SEPTIC SHOCK, ANTIINFLAMMATORY AND ANTIALLERGENS | GLAXO WELLCOME INC. (US) | 1998-07-07 | — | — | US | disclosed |
| EP-0775141-A1 | PHENYL XANTHINE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004280-A1 | PHENYL XANTHINE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072861-A1 | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders | PTGS2, PTGES2, PTGIS | ADORA2B 517/4885ADORA3 2011/4885ADORA2A 666/4885 |
| US-20030181471-A1 | Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-YI)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders | NOD1, PURB, NOD2 | ADORA2B 617/4885ADORA3 609/4885ADORA2A 996/4885 |
| US-20040034020-A1 | Methods of treating periodontal disease | MMP8, LPO, PTGES3 | ADORA2B 680/4885ADORA3 730/4885ADORA2A 660/4885 |
| US-20020035156-A1 | Combination therapy in the prevention of cardiovascular disorders | FABP3, TNNT2, TNNI3 | ADORA2B 705/4885ADORA3 1185/4885ADORA2A 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.